IS TREATMENT-RESISTANCE IN PSYCHIATRIC DISORDERS A TRAP FOR POLYPHARMACY?

被引:0
|
作者
Jasovic-Gasic, Miroslava [1 ]
机构
[1] Univ Belgrade, Fac Med, Acad Med Sci, Serbian Med Soc, Belgrade 11000, Serbia
关键词
treatment resistance; polypharmacy; schizophrenia; psychiatric disorders; DOPAMINE SYNTHESIS CAPACITY; NEGATIVE SYMPTOMS; DOUBLE-BLIND; 2ND-GENERATION ANTIPSYCHOTICS; ELECTROCONVULSIVE-THERAPY; CHRONIC-SCHIZOPHRENIA; CLOZAPINE TREATMENT; CLINICAL-RESPONSE; METAANALYSIS; AUGMENTATION;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Nowadays, more and more mental health professionals manage patients who fail treatment for major psychiatric disorders. There is not a consensus on how to deal with treatment-resistance patients, but usually psychiatrists result to polypharmacy. Method: In reviewing the evidence based clinical research we will try to answer some questions about treatment-resistant psychiatric disorders. Treatment-resistant symptoms complicate the clinical course of all psychiatric disorders especially schizophrenia, causing the patients not to reach the therapeutical goal and enter remission. In consequence, polypharmacy is used to try to deal with the remaining symptoms, raising other issues. Summary: We will try to deal with this problematic issue through clinical studies and major research done to try and answer the question posed.
引用
收藏
页码:308 / 313
页数:6
相关论文
共 50 条
  • [31] Mitochondrial Transplantation in Animal Models of Psychiatric Disorders: A Novel Approach to Psychiatric Treatment
    Iwata, Keiko
    Noguchi, Masafumi
    Shintani, Norihito
    BIOMOLECULES, 2025, 15 (02)
  • [32] Early Identification of Psychiatric Disorders
    Lee, Tae Young
    Kim, Minah
    Kwon, Jun Soo
    FRONTIERS IN PSYCHIATRY: ARTIFCIAL INTELLIGENCE, PRECISION MEDICINE, AND OTHER PARADIGM SHIFTS, 2019, 1192 : 341 - 352
  • [33] Neurogenic hypothesis and psychiatric disorders
    Lau, Benson WuiMan
    Lee, Jada ChiaDi
    So KwokFai
    CHINESE SCIENCE BULLETIN, 2013, 58 (26): : 3188 - 3198
  • [34] Obesity in Adolescents with Psychiatric Disorders
    Chao, Ariana M.
    Wadden, Thomas A.
    Berkowitz, Robert I.
    CURRENT PSYCHIATRY REPORTS, 2019, 21 (01)
  • [35] The Use of Zonisamide for the Treatment of Psychiatric Disorders: A Systematic Review
    Buoli, Massimiliano
    Grassi, Silvia
    Ciappolino, Valentina
    Serati, Marta
    Altamura, Alfredo C.
    CLINICAL NEUROPHARMACOLOGY, 2017, 40 (02) : 85 - 92
  • [36] THE ROLE OF ANTI-INFLAMMATORY TREATMENT IN PSYCHIATRIC DISORDERS
    Mueller, Norbert
    PSYCHIATRIA DANUBINA, 2013, 25 (03) : 292 - 298
  • [37] Sex differences in psychiatric polypharmacy
    Hausner, Helmut
    Wittmann, Markus
    Hajak, Goeran
    Haen, Ekkehard
    PSYCHOPHARMAKOTHERAPIE, 2008, 15 (01): : 21 - +
  • [38] Polypharmacy in Osteoporosis Treatment
    McConnell, Megan
    Shieh, Albert
    CLINICS IN GERIATRIC MEDICINE, 2022, 38 (04) : 715 - 726
  • [39] PHYSICAL COMORBIDITY AND POLYPHARMACY IN OLDER PSYCHIATRIC-PATIENTS
    LACRO, JP
    JESTE, DV
    BIOLOGICAL PSYCHIATRY, 1994, 36 (03) : 146 - 152
  • [40] Medications between psychiatric and addictive disorders
    Lalanne, Laurence
    Lutz, Pierre-Eric
    Trojak, Benoit
    Lang, Jean-Philippe
    Kieffer, Brigitte L.
    Bacon, Elisabeth
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2016, 65 : 215 - 223